Haldol (Haloperidol)

Haloperidol (brand name Haldol) is prescribed for a range of psychiatric conditions and behavioral symptoms.

• Schizophrenia, including maintenance therapy and relapse prevention.
• Acute psychotic episodes, such as those associated with bipolar disorder or substance‑induced states.
• Tourette syndrome, to reduce motor and vocal tics.
• Severe agitation or aggression, particularly when rapid control is required.
• Off‑label use for certain behavioral disturbances in dementia, when other options are unsuitable.
• Adjunctive treatment for psychosis in Parkinson’s disease when benefits outweigh motor side effects.

Haloperidol may produce a range of adverse effects that vary in frequency and severity.

Common

• Drowsiness or sedation, which may affect alertness and coordination.
• Extrapyramidal symptoms such as tremor, muscle rigidity, or akathisia (restlessness).
• Dry mouth, constipation, and reduced gastrointestinal motility.
• Blurred vision, dizziness, or orthostatic light‑headedness.
• Weight gain or changes in appetite.

Serious

• Neuroleptic malignant syndrome, a rare but potentially fatal reaction characterized by high fever, muscle rigidity, and autonomic instability.
• Cardiac arrhythmias, including torsades de pointes or prolonged QT interval, which can lead to syncope or sudden death.
• Severe hypotension or syncope, especially when standing quickly after a dose.
• Elevated liver enzymes indicating possible hepatic injury.

When prescribing haloperidol, clinicians consider several precautionary factors to minimize risk and ensure safe use.

• Assess for a history of cardiovascular disease, as haloperidol can affect heart rhythm.
• Monitor for signs of extrapyramidal symptoms, especially in patients with Parkinsonian features.
• Use caution in patients with hepatic or renal impairment; dose adjustments may be required.
• Evaluate pregnancy and breastfeeding status, because safety data are limited.
• Review concomitant medications that prolong the QT interval.
• Consider age‑related sensitivity, particularly in elderly patients at risk of falls.

Haloperidol can interact with other medicines, altering its effectiveness or increasing the chance of adverse reactions.

Avoid

• Concurrent use with other strong dopamine antagonists, which may intensify extrapyramidal effects.
• Combining with medications that markedly prolong the QT interval, such as certain antiarrhythmics or fluoroquinolones.
• Use with MAO inhibitors, which can increase the risk of severe hypotension.

Use with caution

• Co‑administration with anticholinergic agents; they may mask early signs of extrapyramidal symptoms.
• Concurrent CNS depressants (e.g., benzodiazepines, opioids) may enhance sedation.
• Adjust dose when given with CYP3A4 inhibitors or inducers, as they affect haloperidol metabolism.